1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Tome Biosciences Acquires Replace Therapeutics

M&A Deal Summary

Tome Biosciences Acquires Replace Therapeutics

On January 2, 2024, Tome Biosciences acquired life science company Replace Therapeutics

Acquisition Highlights
  • This is Tome Biosciences’ 1st transaction in the Life Science sector.
  • This is Tome Biosciences’ 1st transaction in the United States.
  • This is Tome Biosciences’ 1st transaction in California.

M&A Deal Summary
Date 2024-01-02
Target Replace Therapeutics
Sector Life Science
Buyer(s) Tome Biosciences
Deal Type Add-on Acquisition

Target

Replace Therapeutics

Berkeley, California, United States
Replace Therapeutics is a biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequences. Replace Therapeutics was founded in 2022 and is based in Berkeley, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Tome Biosciences

Watertown, Massachusetts, United States
Category Company
Founded 2021
Sector Life Science
DESCRIPTION

Tome Biosciences is a programmable genomic integration (PGI) company. The technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies. Tome Biosciences was founded in 2021 and is based in Watertown, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal